Navigation Links
Diamyd(R) Study Published in Prestigious New England Journal of Medicine
Date:10/9/2008

STOCKHOLM, October 9 /PRNewswire-FirstCall/ -- Diamyd Medical reports that the world's most influential medical journal, the New England Journal of Medicine, has published an article with results from the company's study of the Diamyd(R) diabetes vaccine for type 1 diabetes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 )

The article is now available on the journal's web site (http://www.nejm.org) and will be in print on October 30. It presents the results of the concluded Phase II study of the Diamyd(R) diabetes vaccine. The article provides detailed information about the study, which showed that Diamyd(R) helped children and adolescents with type 1 diabetes, who participated in the study, retain the ability to produce their own insulin without causing any serious side effects.

"The results show that treatment with Diamyd(R) clearly has a positive effect on the course of type 1 diabetes, the most common serious, chronic disease among children," says Professor Johnny Ludvigsson at Linkoping University Hospital, who is first author of the article and responsible for the study.

The New England Journal of Medicine is the world's oldest and most influential medical journal, recognized for the high scientific standards of its content. Every year they receive more than 5,000 scientific articles from around the world, but only a fraction of them are selected for publication. Articles published in the journal are often noted over the entire world and reach many researchers, doctors and other interested parties.

"This is the ultimate scientific validation of the study results," says Peter Zerhouni, Director of Business Development at Diamyd and co-author of the article. "The material was reviewed and scrutinized several times by experts from different areas before publication."

"That our
'/>"/>

SOURCE Diamyd Medical AB (publ)
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
2. Wild Blueberries Take Top Spot in New Antioxidant Research Study
3. National Study Presented at ACG 2008 Confirms New Device Functions Like Rear-View Mirror to Provide Improved View of the Colon
4. Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period
5. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
6. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
7. New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohns Disease According to First-of-its Kind Study
8. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
9. Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study
10. The Childrens Hospital of Philadelphia Announces New Regional Participant in The National Childrens Study
11. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of novel bile ... primary biliary cirrhosis, today announced that Mark ... will present at the Deutsche Bank Securities 38th Annual ... on Wednesday, May 29, 2013 at 4:10 p.m. ET. ...
(Date:5/23/2013)... 23, 2013  Inhibikase Therapeutics, Inc., an emerging ... it will present new results on its antiviral ... sponsored by the PML Consortium (composed of Pfizer, ... (JCV) is the causative agent of Progressive Multifocal ... in an extended release formulation, can clear JC ...
(Date:5/23/2013)... -- PAREXEL International Corporation (NASDAQ: PRXL ) announced ... Healthcare Conference in New York.  James Winschel, ... will be making a presentation on PAREXEL and discussing ... 2013. A live webcast of the presentation ... website at www.PAREXEL.com in the Upcoming Events ...
Breaking Medicine Technology:Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2PAREXEL International To Present At Jefferies Healthcare Conference 2
... (NASDAQ: AMRI ), a global contract services organization ... as part of its ongoing global operations review to improve ... its European operations focused on a reduction of the workforce ... at its Budapest, Hungary operation. As a ...
... Jan. 9, 2012  Xenon today announced a strategic alliance ... RO, ROG; OTCQX: RHHBY), to discover and develop compounds ... "We are delighted to be collaborating with ... "Genentech is among the world,s leading biotech companies and ...
Cached Medicine Technology:AMRI Announces Review of Its Hungary Operation 2AMRI Announces Review of Its Hungary Operation 3Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics 2
(Date:5/23/2013)... characterized as "triple negative" carries a poor prognosis, with ... kill the cancer cells the way it,s supposed to. ... cells don,t respond to chemotherapy, and identifies a mechanism ... Dr. Shawn Li, PhD, and his team at Western,s ... protein called Numb functions to promote the death of ...
(Date:5/23/2013)... Former United States Vice President Dick Cheney served ... Paramedic Luncheon. , In front of 1,500 guests ... medics, saying, "I am delighted to be here to ... of the Year Award. I think it's a tremendous ... within a company like this because there are obviously ...
(Date:5/23/2013)... May 23, 2013 On April 29th, 2013, ... midst of growing numbers of H7N9 cases and deaths. The ... Bird Flu Cases Will Subside in Northern Hemisphere as Available ... new cases have been reported. , Quoting Kevin McGuire, ... as predictable as flowers budding in the spring and leaves ...
(Date:5/23/2013)... EnvirOasis, the leader in energy efficient ... is pleased to announce its new line of Energy ... EnvirOasis has been a market leader in Fluorescent ... and has recently brought to market a full line ... is energy efficient lighting technology which produces a very ...
(Date:5/23/2013)... Doheny HealthDay Reporter , , THURSDAY, May 23 (HealthDay ... dropping sharply, especially among Hispanic teens, according to a new ... aged 15 to 19 dropped by nearly one half from ... 1,000 teens to 31 births for every 1,000. From ... fell 25 percent, from 41.5 to about 31. During ...
Breaking Medicine News(10 mins):Health News:Acadian Ambulance Honors Paramedic of the Year at Annual Luncheon 2Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 2Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 3Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:U.S. Teen Birth Rate Plummets: Report 2Health News:U.S. Teen Birth Rate Plummets: Report 3
... Spanish psychologists and a German neurologist have recently shown that ... noun is different from the part used when a verb ... using functional magnetic resonance, according to an article they have ... "Learning nouns activates the left fusiform gyrus, while learning verbs ...
... not helped patients, says AMA president , THURSDAY, Feb. 25 ... vanishing, according to an American Medical Association report that looked ... In 24 of the states, the two largest insurers had ... year, 18 of 42 states had that type of market ...
... ... ... Advans, a solution provider and IT consulting firm, has announced today, the results of ... IT Outsourcing Survey, 75 percent of executives prefer outsourcing domestically rather than offshore. ...
... ... Sports Medicine (AOSSM), in partnership with Genzyme Biosurgery, is pleased to announce a new ... OA progression. , ... Rosemont, IL (Vocus) February 25, 2010 -- The American Orthopaedic Society for Sports ...
... ... Distributors continue to await their orders of Xyngular Xyng™ as Zija,s ... beat Xyngular™ to market months before their NEW! Xyng™ product was ... since. People from all over the world are calling to become ...
... ... clean hands and defense against colds and H1N1 flu virus as near as your closest ... to prevent infection and illness. Now teachers in classrooms anywhere can encourage frequent hot-water hand-washing ... ...
Cached Medicine News:Health News:Nouns and verbs are learned in different parts of the brain 2Health News:Nouns and verbs are learned in different parts of the brain 3Health News:Health Insurance Competition Vanishing: Study 2Health News:Advans Survey Reveals that 75 Percent of Executives Prefer Domestic Outsourcing vs. Offshore 2Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 2Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 3Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 2Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 3Health News:Angeles Launches New Portable Hot Water Sinks 2Health News:Angeles Launches New Portable Hot Water Sinks 3Health News:Angeles Launches New Portable Hot Water Sinks 4
This 1000 L tip is the equivalent to the "Blue" tips and fits nearly every manufacturer's 1000 L pipettor....
This 500 tip allows you to draw the full volume of compatible Biohit and Eppendorf pipettors....
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
MBP's 200 ul large orifice tip is perfect for handling fragile cells, viscous samples, and genomic DNA....
Medicine Products: